Ignite Creation Date:
2025-12-25 @ 12:21 AM
Ignite Modification Date:
2026-05-17 @ 2:33 PM
Study NCT ID:
NCT03089658
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2019-10-09
First Post:
2017-03-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)
Sponsor:
Merck KGaA, Darmstadt, Germany
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Metastatic Merkel Cell Carcinoma | View |